Nalaganje...
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance
Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, e...
Shranjeno v:
| izdano v: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
AME Publishing Company
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5233880/ https://ncbi.nlm.nih.gov/pubmed/28149764 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2016.12.02 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|